The activist hedge fund’s 2017 performance was buoyed by a large position in Twenty-First Century Fox.
Stephen TaubJanuary 31, 2018
Jeffrey Ubben, ValueAct Capital ValueAct Capital continues to thrive despite holding onto Valeant Pharmaceuticals, the troubled drug company whose stock crashed spectacularly in the fall of 2015, and hasn’t recovered since. The
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.